Top Markets
#1 Status Status +19.34%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.51%
#3 GoPlus Security GoPlus Security +14.26%
#4 Ontology Gas Ontology Gas +12.27%
#5 DMT-NAT DMT-NAT +8.99%
#6 Nillion Nillion +7.04%
#7 Provenance Blockchain Provenance Blockchain +7.02%
#8 Janction Janction +6.49%
#9 Cap Cap +6.34%
#10 Bedrock Bedrock +5.75%
Coin of the day
Status Status
Einstellungen
Sprache
DEUTSCH
Währung
USD
Thema
Renalytix Plc Renalytix Plc

Renalytix Plc

RNLX
Rang in Aktien #33998
Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc... Renalytix Plc, established in New York in 2018 and known as Renalytix AI plc until its name change in June 2021, focuses on creating artificial intelligence-driven in vitro diagnostic tools for kidney ailments. Its primary product, KidneyIntelX, is an advanced diagnostic system that utilizes an AI-powered algorithm. This algorithm integrates multiple data sources, including scientifically validated blood markers, genetic predispositions, and individual patient information from electronic health records, to produce a distinct risk score for kidney disease. The company's technology is applied in various areas: identifying and predicting the course of kidney disease, informing clinical treatment, selecting patients for pharmaceutical trials, and discovering new therapeutic targets. Renalytix has formed several strategic collaborations, such as licensing agreements with Mount Sinai Health System for AI-assisted kidney disease diagnosis, with Joslin Diabetes Center, Inc. for developing biomarker-based kidney disease prediction products, and with Kantaro Biosciences LLC for laboratory tests to detect SARS-CoV-2 antibodies. Furthermore, it has partnered with Atrium Health, Wake Forest Baptist Health, and Wake Forest School of Medicine to introduce an innovative clinical care model aimed at improving kidney health outcomes and preventing disease advancement and failure in vulnerable populations.
Aktienkurs
$0.1502
Zuletzt synchronisiert: 2024-11-04
Marktkapitalisierung
$6.43M
Veränderung (1 Tag)
-5.45%
Veränderung (1 Jahr)
0.00%
Land
US
Handel Renalytix Plc (RNLX)

Kategorie

Healthcare
Umsatz von Renalytix Plc (RNLX)
Umsatz im Sep 2024 TTM: $2.35M
Laut den aktuellen Finanzberichten von Renalytix Plc beträgt der derzeitige Umsatz des Unternehmens (TTM) $2.35M. Im Jahr 2023 erzielte das Unternehmen einen Umsatz von $3.40M eine Steigerung gegenüber dem Umsatz im Jahr 2022, der $2.97M betrug. Der Umsatz ist der Gesamtbetrag, den ein Unternehmen durch den Verkauf von Waren oder Dienstleistungen erzielt. Im Gegensatz zum Gewinn werden keine Ausgaben abgezogen.
Umsatzverlauf für Renalytix Plc von 2018 bis 2026
Umsatz am Ende jedes Jahres
Jahr Umsatz ändert
2026 (TTM) $2.35M 2.75%
2024 $2.29M -32.74%
2023 $3.40M 14.58%
2022 $2.97M 99.20%
2021 $1.49M 0.00%
2020 0.00 0.00%
2019 0.00 0.00%
2018 0.00 0.00%
Umsatz vergleichbarer Unternehmen oder Wettbewerber
Unternehmen Umsatz Umsatzunterschied Land
GE HealthCare Technologies Inc. GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc.
GEHC.US
 $20.24B 860,571.77%
US
Pro Medicus Limited Pro Medicus Limited
Pro Medicus Limited
PME.AX
 $160.46M 6,722.29%
AU
BrightSpring Health Services, Inc. Common Stock BrightSpring Health Services, Inc. Common Stock
BrightSpring Health Services, Inc. Common Stock
BTSG.US
 $14.37B 610,937.33%
US
Tempus AI, Inc. Tempus AI, Inc.
Tempus AI, Inc.
TEM.US
 $1.43B 60,785.16%
US
Signify Health, Inc. Signify Health, Inc.
Signify Health, Inc.
SGFY.US
 - -
US